June 1, 2011
Stuart Mill Venture Partners Invests in Marrone Bio Innovations Series C Round
Stuart Mill Venture Partners, L.P. (SMVP) today announced participation in the recent Series C closing of an institutional round of financing for Marrone Bio Innovations, Inc. (MBI). New investors in this Series C preferred financing are Syngenta Ventures, Mitsui Global Investment, and a family investment trust. Existing investors include Stuart Mill Venture Partners, Contrarian Group, Saffron Hill Ventures, One Earth Capital, Clean Pacific Ventures, and Calvert Equity Portfolio, in addition to several individuals. Contrarian Group's CFO, Tim Fogarty has joined the Board.
The financing, which totaled $25.4 million, is being used to expand global sales of Regalia® Biofungicide, to launch Zequanox™ and other pipeline products upon EPA approval and for development of new nematicides, herbicides, and fungicides from the discovery screen. "We are very pleased to receive investment from new investors and to have the support of our existing investors. Their size and prominence as well as the amount funded recognize our rapid progress in the marketplace, unsurpassed product pipeline, and unique discovery capability," said Dr. Pam Marrone, MBI's Founder and CEO.
For more information contact Stuart Mill Venture Partners from this site or visit www.marronebioinnovations.com.
Stuart Mill Venture Partners, L.P. (SMVP) today announced participation in the recent $12 million Series D closing led by eXome Capital. Other private and existing investors also participated. Appistry plans to use this additional funding to support growth by expanding sales and marketing efforts, which is expected to bring the company to profitability. This Series D offering, which includes term debt, pushes the total private investment in Appistry to over $34 million.
"With the exponential growth in the depth and complexity of 'big data' applications, the critical challenges behind storing, managing and analyzing data efficiently and sustainably will only continue to rise in significance," Appistry CEO Kevin Haar said. "This latest round of funding is optimally timed to fuel Appistry's natural evolution up the value chain to provide specific solutions to real customer problems."
The relative simplicity and cost-efficiencies provided by Appistry's scalable cloud solutions are particularly relevant to super-throughput applications within the financial services, life science, and defense and intelligence sectors.
"Appistry arms its customers with a powerhouse value proposition by shattering the boundaries left behind by legacy 'big iron' processing and storage models," Sultan Meghji, Appistry's Vice President of Cloud Applications, said. "The next generation of high-performance computing is happening right here."
For more information contact Stuart Mill Venture Partners from this site or visit www.appistry.com.
